Clinicopathological and prognostic significance of caveolin-1 and ATG4C expression in the epithelial ovarian cancer

Zeng, Yuyang; Chen, Mengxi; Ganesh, Sridha; Hu, Shunze; Chen, Honglei

doi:10.1371/journal.pone.0232235

Cited by 6 publications

(4 citation statements)

References 44 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sanna et al [13] found that CAV1 exerts a functional activity mediated, by directly binding to sequences of genes involved in proliferation in ovarian carcinoma cells. Zeng [14] and other studies found the correlation between the expression of CAV1 and clinicopathological parameters of ovarian cancer and its relationship with the prognosis.…”

Section: Ivyspringmentioning

confidence: 79%

“…The AUROC of plasma exosomal CAV1 were 0.76 (95% CI: 0.68-0.82) and 0.78 (95% CI: 0.70-0.84) for DFS and OS prediction in ovarian cancer patients, respectively. Plasma exosomal CAV1 levels has a better performance for OS and DFS prediction in ovarian cancer patients than CAV1 protein and/or mRNA and is a useful prognostic biomarker [14,34].…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, there has been an increase in studies on the expression and biological roles of CAV1 in ovarian cancer. Zeng et al [14] showed that decreased expression of CAV1 mRNA in epithelial ovarian cancer (EOC) can predict poor overall survival. Expression of CAV1 protein in cancer cells is significantly associated with histological subtype of EOC, suggesting that CAV1 could serve as a useful prognostic biomarker and candidate therapeutic target in EOC.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Plasma exosomal caveolin-1 predicts Poor Prognosis in Ovarian Cancer

Yang¹,

Wu²,

Zhu³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Objective: In this study, we aimed to evaluate the levels of plasma exosomal caveolin-1(CAV1) and determine its prognostic value in ovarian cancer patients. Patients and Methods: Exosome-rich fractions were isolated from the plasma of 155 patients with ovarian cancer. TEM, NTA and western blot analysis were used to confirm the exosome integrity and purification. Results: Compared with healthy controls, plasma exosomal CAV1 levels in ovarian cancer patient were significantly down-regulated (P < 0.001). The low plasma levels of exosomal CAV1 in ovarian cancer patient plasma were related to FIGO stages, grades and lymph node metastasis (all P < 0.01). Among all ovarian cancer patients, DFS was worse in patients who had low plasma exosomal CAV1 levels compared with that in patients with high plasma exosomal CAV1 levels (P < 0.001). The OS of patients with low plasma exosomal CAV1 levels was shorter than that in patients with high plasma exosomal CAV1 levels (P < 0.001). The AUROC of plasma exosomal CAV1 was 0.76 (95% CI: 0.68-0.82) for DFS prediction in ovarian cancer patients, with a sensitivity 52.9 (95% CI: 42.8-62.9) and a specificity 88.7 (95% CI: 77.0-95.7). For OS prediction in ovarian cancer patients, the AUROC of plasma exosomal CAV1 was 0.78 (95% CI: 0.70-0.84), with a sensitivity 65.1 (95% CI: 49.1-79.0) and a specificity 81.2 (95% CI: 72.8-88.0). Conclusions: Low exosomal CAV1 levels were closely related to the FIGO stages I/II, low grade, lymph node metastasis and prognosis of ovarian cancer patients. Plasma exosomal CAV1 may be a potential biomarker for the prognosis in ovarian cancer patients.

show abstract

Section: Ivyspringmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma exosomal caveolin-1 predicts Poor Prognosis in Ovarian Cancer

Yang¹,

Wu²,

Zhu³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

show abstract

“…In glioma, expression of ATG4C associated with overall survival of the patient and median relapse-free survival in patients with low ATG4C was significantly higher than that of patients with high ATG4C expression 17 . In epithelial ovarian cancer, overall survival of patients with low ATG4C tumor expression was significantly longer than that of patients with high tumor expression of ATG4C, and the expression of ATG4C correlated with that of caveolin-1 18 . Other human diseases in which ATG4C has been described as important include Kashin-Beck Disease, a form of osteoarthritis characterized by multi-joint deformities and retardation of skeletal growth 19 ; SNPs in ATG4C significantly associate with risk of developing KBD and chondrocytes from patients with KBD express significantly lower levels of ATG4C than in controls 19 .…”

Section: Discussionmentioning

confidence: 95%

Autophagin-3 (ATG4C) is differentially expressed in the brains of patients with Parkinson’s Disease.

Mamoor¹

2020

Preprint

View full text Add to dashboard Cite

Parkinson’s Disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra of the basal ganglia (1). We mined published microarray datasets (2, 3) to identify genes whose expression was most different in the substantial nigra of patients with PD as compared to that of non-affected patients. We identified significant changes in expression of the gene encoding autophagin-3 (ATG4C) in the substantia nigra of patients with PD.

show abstract